Aligos Therapeutics
ALGS
76 hedge funds and large institutions have $68.4M invested in Aligos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 15 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
7% more funds holding
Funds holding: 71 → 76 (+5)
0.11% less ownership
Funds ownership: 3.09% → 2.98% (-0.11%)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
82% less capital invested
Capital invested by funds: $390M → $68.4M (-$322M)
96% less call options, than puts
Call options by funds: $2K | Put options by funds: $48K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.72M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.21M |
| 4 |
Renaissance Technologies
New York
|
+$986K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$618K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$36.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.9M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.19M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$2.24M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.13M |
ALGS Hedge Fund Activity: Q1 2022 in Review
76 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2022, worth a combined $68.4M — down 82% from $390M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ALGS positions and 15 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $12.4M. The largest seller was Logos Global Management, exiting entirely with an estimated $36.9M sold.
- 76 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2022, up from 71 in Q4 2021.
- Funds reported $68.4M of Aligos Therapeutics stock for Q1 2022, down 82% quarter-over-quarter.
- 20 funds opened new Aligos Therapeutics positions in Q1 2022 and 15 closed out, a net change of +5 holders.
- The largest Aligos Therapeutics buyer in Q1 2022 was EcoR1 Capital, an estimated $12.4M added.
- The largest Aligos Therapeutics seller in Q1 2022 was Logos Global Management, an estimated $36.9M sold.
Based on aggregated 13F filings for Q1 2022.